A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis
Kim Papp, Sigrid Balser, Katrin Nopora, Piotr Rewerski, Brigitte Freudensprung, Michael Trieb
Springer Nature ·
2025-03-06
· DOI 10.1007/s12325-025-03138-2
The publisher did not provide an abstract — full text is available via the link below.
Kim Papp, Sigrid Balser, Katrin Nopora, Piotr Rewerski, Brigitte Freudensprung, Michael Trieb. A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis. // Advances in Therapy. – 2025. – DOI: 10.1007/s12325-025-03138-2. – URL: https://doi.org/10.1007/s12325-025-03138-2
Kim Papp, Sigrid Balser, Katrin Nopora, Piotr Rewerski, Brigitte Freudensprung, & Michael Trieb (2025). A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis. Advances in Therapy. https://doi.org/10.1007/s12325-025-03138-2
Kim Papp, et al. “A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis.” Advances in Therapy, 2025. doi:10.1007/s12325-025-03138-2.
@article{Papp2025,
title = {A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis},
author = {Papp, Kim and Balser, Sigrid and Nopora, Katrin and Rewerski, Piotr and Freudensprung, Brigitte and Trieb, Michael},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03138-2},
url = {https://doi.org/10.1007/s12325-025-03138-2}
}